GSK 2981278

Drug Profile

GSK 2981278

Alternative Names: GSK-2981278

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antipsoriatics
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis

Most Recent Events

  • 02 Jan 2017 GlaxoSmithKline plans a phase II trial for Plaque psoriasis in Germany (Topical, Ointment) (NCT03004846)
  • 01 Feb 2016 GlaxoSmithKline completes a phase I trial in Plaque psoriasis in Germany (Topical) (NCT02548052)
  • 01 Oct 2015 Phase-I clinical trials in Plaque psoriasis in Germany (Topical) (NCT02548052)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top